Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.48 |
| ▸ | ITGA1 | P56199 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249688 | 0.86 | UTS2R (0.54) | PPARGUTS2RALDH1A1LMNACDK1 | |
| SCHEMBL6542141 | 0.86 | UTS2R (0.49) | UTS2RMAPTALDH1A1HTTMEN1 | |
| SCHEMBL6542576 | 0.85 | UTS2R (0.60) | PPARGUTS2RMAPTALDH1A1HTT | |
| SCHEMBL6541415 | 0.85 | UTS2R (0.48) | PPARGUTS2RMAPTALDH1A1HTT | |
| SCHEMBL6542775 | 0.83 | UTS2R (0.52) | UTS2RMAPTALDH1A1HTTMEN1 | |
| SCHEMBL6542101 | 0.83 | HSD17B1 (0.50) | UTS2RMAPTALDH1A1HTTMEN1 | |
| SCHEMBL6542115 | 0.83 | UTS2R (0.48) | UTS2RITGA1MAPTALDH1A1HTT | |
| SCHEMBL6542874 | 0.83 | LMNA (0.51) | UTS2RMAPTALDH1A1HTTMEN1 | |
| SCHEMBL6543082 | 0.82 | LMNA (0.52) | UTS2RMAPTALDH1A1HTTMEN1 | |
| SCHEMBL7247677 | 0.81 | UTS2R (0.49) | UTS2RMAPTALDH1A1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | claimed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | disclosed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100580-A1 | Urotensin-II receptor antagonists | UTS2R, TMPRSS4, PLAUR | PPARG 3491/4885UTS2R 1/4885ITGA1 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.